News Focus
News Focus
icon url

dennisdave

08/12/25 5:52 PM

#781016 RE: dennisdave #781014

From ChatGTP

Alright — let’s walk through Scenario 1: CHM end-June ? new questions ? another RFI and work out the realistic and outer-limit decision windows.
Knowns & Assumptions
CHM meeting: 26–27 June 2025

New questions issued: Let’s assume MHRA formulated the RFI within ~7–14 days after CHM (by ~5–10 July).
RFI response time allowed:
MHRA guidance: up to 90 calendar days for a sponsor to respond to an RFI.
NWBO historically uses long response windows (especially for final RFI rounds).

Transition period: MHRA guidance adds ~3 days admin time after a response before the next clock-on.
Final MHRA review after last RFI: Typically ~30–40 days clock-on for final assessment and decision.

Timeline calculation (outer limit)
Step Date Range
RFI issued ~5–10 July 2025
NWBO takes full 90 days to ~3–8 October 2025
+3 days transition to ~6–11 October 2025
Final MHRA clock-on (30–40 days) to ~5–20 November 2025
Decision notification to NWBO ~5–20 November 2025
Public announcement 1–5 business days later

Outer limit: Mid-to-late November 2025 for public disclosure if they use every day available
.
More likely if NWBO responds faster
If NWBO responds in, say, 60 days instead of 90:
RFI response due: early September
MHRA final review complete: early-to-mid October

Public disclosure: October 2025
Conclusion
Fastest plausible: early October 2025 announcement
Slowest plausible: mid-to-late November 2025 announcement


Given NWBO’s historic pace, late October. Early November feels most realistic if we’re indeed in the “third RFI” phase now.
icon url

manibiotech

08/12/25 6:13 PM

#781021 RE: dennisdave #781014

Reply means it was most likely discussed in the meeting . But doesn't sound either positive or negative as CHM could decide either way ?
icon url

muee88

08/12/25 9:58 PM

#781067 RE: dennisdave #781014

The reply implies nothing of the sort. It just means they have the May 2025 and June 2025 meeting summaries, not that a brain cancer treatment was discussed during those meetings.